Setup. RVMD is the biotech story of 2026 — daraxonrasib Phase 3 in 2L PDAC hit with OS HR 0.40 (April 13), $2.14B equity raise absorbed at $142 in one day, ASCO plenary in 15 days, NDA on rolling submission under the new Commissioner's National Priority Voucher. Stock $149, mean target $159.53. We've been tracking this through the Q1 2026 call (May 6) and parallel 10-Qs. The case for owning RVMD is widely understood. The case for not owning it — and where the actual mispricing lives — is not.

What the filing says

• ITT all-comer: 60% death risk reduction "with OR without an identified RAS mutation" (Goldsmith). Implies all-comer label, ≈18K US 2L PDAC addressable.
• Launch: US sales force in "final stages of onboarding"; APAC/Japan/Germany GMs appointed. EAP approved with FDA safe-to-proceed.
• RM-055 (catalytic RAS(ON) inhibitor): Phase 1 IND H2 2026, beats daraxonrasib resistance, "new class." Cross-corpus search of 10,618 transcripts: zero competitor uses this mechanism language. Not yet in any SEC filing.
• APEX-103 (daraxonrasib + Summit ivonescimab): dosing patients in NSCLC, PDAC, CRC. Zero economic terms (no upfront, no milestones, no royalty). Corroborated in both Q1 10-Qs.
• RPRX synthetic royalty: zero call mention. $4.0B total cash post-raise.

Buried in the 10-Qs (May 6/11): On April 24, RVMD sent ERAS a cease-and-desist letter alleging (1) ERAS-0015 infringes US Patent 12,409,225 under doctrine of equivalents, (2) trade secret misappropriation via Joyo Pharmatech, (3) improperly comparative preclinical claims. Three days BEFORE ERAS released Phase 1 data April 27: 62% uORR8wk NSCLC, 40% PDAC, one Grade 5 (fatal) pneumonitis. Combo data slipped H2 2026 → H1 2027.

What the market thinks

RVMD $149, mean target $159.53 (7% upside), 21 analysts 100% bullish. Probability-weighted forward EV (12mo): ≈5.4%. Empirical: idio variance 65.8% (BELOW Paleologo's 75% threshold), beta 1.41, α/σ_idio ≈ 0.25. Raw Sharpe 0.14; after factor stripping, α ≈ 0.

Why the gap exists — at RVMD, it doesn't

RVMD is fully covered: $30B cap, 21 analysts, zero dispersion. Consensus pathway (Q3 NDA → Q4/Q1 approval → launch) is priced. "No edge" is not pessimism — it's empirical: idio below target, factor loadings high.

Where the gap is (cross-ticker): SMMT (Summit Therapeutics). Ivonescimab BLA accepted, HARMONi PFS HR 0.52, PDUFA Nov 14, 2026. Empirical: $18.14, idio 78.6% (clean), short interest 21.6% (extreme — market positioned for rejection), MOM1Y -21.4%, RSI 34. Market-implied approval probability ≈55% (inferred from short interest). Reasonable P 75% — base rate for oncology BLA with positive Phase 3 HR <0.6 in unmet need is 80-85%, discounted for Akeso/Chinese-origin data (sintilimab 2022 ODAC 14-1 against precedent) and first-in-class mechanism. 20pp gap. Plus APEX-103 is free option-value bull skew.

Risks (ranked)

1. RVMD manufacturing CRL — third-party manufacturer identity undisclosed. ACHV precedent (May 12: CRL expected June 20 due to manufacturer OAI) confirms CNPV does NOT bypass GMP inspection. Separable risk to Q3 NDA → Q1 2027 approval timeline.
2. ASCO subgroup heterogeneity — if WT subgroup HR ≈0.55 vs RAS-mutant ≈0.40, label fight, all-comer assumption breaks.
3. ERAS IP resolution — RVMD prevails on injunction → ERAS impaired; settlement on favorable terms or acquisition → squeezes any short. Stock already RSI 17.4 oversold.
4. SMMT ODAC — sintilimab precedent looms for Akeso-origin data.
5. Lock-up overhang (~June 1) — insider shares unlock into ASCO.

Catalysts

• May 21: ASCO embargo lifts 5pm ET
• May 30 – June 3: ASCO plenary, RASolute 302 full subgroup data
• ~June 1: RVMD lock-up expiry
• June 20: ACHV PDUFA (CNPV precedent read)
• Q3 2026: RVMD NDA submission
• Nov 14, 2026: SMMT ivonescimab PDUFA
• Dec 17, 2026: RVMDW warrants expire
• Q1 2027: daraxonrasib FDA decision

What would change our mind

• RVMD: Idio rises to 80%+ on trailing regression with α_orth/σ > 0.5 — reconsider edge. Manufacturer disclosure with OAI/483 deficiencies — reduce approval P. Subgroup HR clean across RAS-mutant AND WT at ASCO — slightly increase confidence in all-comer label (still consensus).
• SMMT: FDA ODAC scheduled for ivonescimab — reduce approval P to 50%. HARMONi-3 confirmatory enrollment slowing — bearish.
• ERAS: Bounce to $13-14 (RSI > 40) + RVMD formal complaint filed — short setup re-emerges. Settlement disclosure or acquisition — thesis dies.

Evidence